Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Aerpio Pharmaceuticals Inc is a biotechnology business based in the US. Aerpio Pharmaceuticals shares (ARPO) are listed on the NASDAQ and all prices are listed in US Dollars. Aerpio Pharmaceuticals employs 12 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$1.70|
|52-week range||$0.95 - $28.76|
|50-day moving average||$31.63|
|200-day moving average||$25.85|
|Wall St. target price||$22.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.41|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-13)||N/A|
|1 month (2021-09-20)||N/A|
|3 months (2021-07-23)||-17.87%|
|6 months (2021-04-23)||47.83%|
|1 year (2020-10-23)||26.87%|
|2 years (2019-10-23)||220.57%|
|3 years (2018-10-23)||2.03|
|5 years (2016-10-20)||N/A|
|Gross profit TTM||$15 million|
|Return on assets TTM||-31.02%|
|Return on equity TTM||-47.61%|
|Market capitalisation||$104.9 million|
TTM: trailing 12 months
There are currently 2.8 million Aerpio Pharmaceuticals shares held short by investors – that's known as Aerpio Pharmaceuticals's "short interest". This figure is 22% down from 3.5 million last month.
There are a few different ways that this level of interest in shorting Aerpio Pharmaceuticals shares can be evaluated.
Aerpio Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Aerpio Pharmaceuticals shares currently shorted divided by the average quantity of Aerpio Pharmaceuticals shares traded daily (recently around 1.5 million). Aerpio Pharmaceuticals's SIR currently stands at 1.81. In other words for every 100,000 Aerpio Pharmaceuticals shares traded daily on the market, roughly 1810 shares are currently held short.
However Aerpio Pharmaceuticals's short interest can also be evaluated against the total number of Aerpio Pharmaceuticals shares, or, against the total number of tradable Aerpio Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aerpio Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Aerpio Pharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.1063% of the tradable shares (for every 100,000 tradable Aerpio Pharmaceuticals shares, roughly 106 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aerpio Pharmaceuticals.
Find out more about how you can short Aerpio Pharmaceuticals stock.
We're not expecting Aerpio Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Aerpio Pharmaceuticals's shares have ranged in value from as little as $0.954 up to $28.76. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aerpio Pharmaceuticals's is 1.6466. This would suggest that Aerpio Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Aerpio Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.